<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90620">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01770353</url>
  </required_header>
  <id_info>
    <org_study_id>MM-398-01-01-02</org_study_id>
    <nct_id>NCT01770353</nct_id>
  </id_info>
  <brief_title>Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent</brief_title>
  <official_title>A Pilot Study in Patients Treated With MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merrimack Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I Pilot study to understand the biodistribution of MM-398 and to determine
      the feasibility of using Ferumoxytol as a tumor imaging agent.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Measure tumor levels of irinotecan and SN-38 (in ng/mL)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile of MM-398 in the presence of ferumoxytol (number and type of Adverse Events compared with histological control)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response Rate measured by RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 guidelines</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of the drug (t 1/2) in number of hours</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>50% of total time of drug in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of drug in plasma (Cmax) in ng/mL</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of drug availability in the plasma (AUC) in ng/mL x hours</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma drug concentration versus time curve</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>ER/PR Positive Breast Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastro-Esophageal Junction Adenocarcinoma</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Ferumoxytol followed by MM-398</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 80 mg/m2 IV over 90 min on Days 1 and 15 of every 4 weekly cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol followed by MM-398</intervention_name>
    <description>Ferumoxytol 5 mg/kg IV at 1mL/sec, given once. MM-398 80 mg/m2 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity</description>
    <arm_group_label>Ferumoxytol followed by MM-398</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of solid tumors, CRC, TNBC, ER/PR Breast Cancer,
             NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer, GEJ adenocarcinoma, Head
             and Neck Cancer

          -  Metastatic disease

          -  ECOG Performance Status 0 to 2

          -  Adequate bone marrow, hepatic and renal function

          -  Normal ECG

          -  18 years of age or above

          -  Able to understand and sign informed consent

        Exclusion Criteria:

          -  Active CNS metastasis

          -  Clinically significant GI disorders

          -  Prior irinotecan or bevacizumab therapy within last 6 months

          -  Known hypersensitivity to MM-398 or ferumoxytol

          -  Inability to undergo MRI

          -  Active infection

          -  Pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliel Bayever, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merrimack Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eliel Bayever, MD</last_name>
    <phone>617-441-1000</phone>
    <email>ebayever@merrimackpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 8, 2013</lastchanged_date>
  <firstreceived_date>December 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumors</keyword>
  <keyword>Triple Negative Breast cancer</keyword>
  <keyword>Non Small Cell Lung cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>MM-398</keyword>
  <keyword>nanoliposomal irinotecan</keyword>
  <keyword>Ferumoxytol</keyword>
  <keyword>ER/PR positive Breast Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Gastro-Esophageal Junction Adenocarcinoma</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ferumoxytol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
